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AbstrAct
background. Accurate target volume segmentation is crucial for success in image-guided radiotherapy. However, variabil-
ity in anatomical segmentation is one of the most significant contributors to uncertainty in radiotherapy treatment planning. 
This is especially true for lung cancer where target volumes are subject to varying magnitudes of respiratory motion.
Material and methods. This study aims to analyze multiple observer target volume segmentations and subsequent 
intensity-modulated radiotherapy (IMRT) treatment plans defined by those segmentations against a reference standard for 
lung cancer patients imaged with four-dimensional computed tomography (4D-CT). Target volume segmentations of 10 
patients were performed manually by six physicians, allowing for the calculation of ground truth estimate segmentations 
via the simultaneous truth and performance level estimation (STAPLE) algorithm. Segmentation variability was assessed 
in terms of distance- and volume-based metrics. Treatment plans defined by these segmentations were then subject to 
dosimetric evaluation consisting of both physical and radiobiological analysis of optimized 3D dose distributions.
results. Significant differences were noticed amongst observers in comparison to STAPLE segmentations and this 
variability directly extended into the treatment planning stages in the context of all dosimetric parameters used in this 
study. Mean primary tumor control probability (TCP) ranged from (22.6  11.9)% to (33.7  0.6)%, with standard 
deviation ranging from 0.5% to 11.9%. However, mean normal tissue complication probabilities (NTCP) based on treat-
ment plans for each physician-derived target volume well as the NTCP derived from STAPLE-based treatment plans 
demonstrated no discernible trends and variability appeared to be patient-specific. This type of variability demonstrated 
the large-scale impact that target volume segmentation uncertainty can play in IMRT treatment planning.
conclusions. Significant target volume segmentation and dosimetric variability exists in IMRT treatment planning 
amongst experts in the presence of a reference standard for 4D-CT-based lung cancer radiotherapy. Future work is needed 
to mitigate this uncertainty and ensure highly accurate and effective radiotherapy for lung cancer patients.
Accurate target volume definition is of paramount 
importance in radiation treatment planning for non-
small cell lung cancer (NSCLC). Thoracic tumors pose 
a challenge for this as they are characteristically subject 
to varying magnitudes of motion due to respiration [1]. 
Lung tumors have been shown to move up to 5 cm 
with free breathing [2] and the magnitude of this motion 
is variable and unpredictable [3]. For image-guided 
radiotherapy (iGRT), three-dimensional computed 
tomography (3D-CT) imaging lacks accurate informa-
tion on tumor motion, providing images with signifi-
cant artifacts that occur due to changes in tumor shape, 
volume, and position due to respiratory motion [4]. 
Manual GTv segmentation variability has previously 
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been demonstrated for lung cancer in 3D image acqui-
sition [5]. Ancillary measures, such as co-registration 
with functional/metabolic imaging and/or automatic 
segmentation strategies, have been shown potential to 
reduce inter- and intra-segmentation variability [6–8].
Due to this uncertainty, intensity-modulated radia-
tion therapy (iMRT) plans based on conventional 
3D-CT images are subject to increased target volume 
margin sizes to account for largely misinterpreted tumor 
locations [3]. using arbitrarily large volumes does not 
address the inherent variability of tumor motion on an 
inter-patient basis and variation in tumor geometry on 
both an inter- and intra-patient basis and limits local 
control during radiotherapy. 4D-CT imaging allows for 
the acquisition of information about changes in tumor 
shape, volume, and location associated with respiratory 
motion in CT image datasets. The basic method for 
target volume segmentation in 4D-CT consists of 
delineating the gross tumor volume (GTv) on each 
respiratory phase based CT dataset (typically 8–12 
phases) with a subsequent internal gross tumor volume 
(iGTv) created by combining multiple GTv segmen-
tation into one enveloped volume [9]. The GTv to 
clinical target volume (CTv) margin expansion of typ-
ical 3D-CT-based radiotherapy (8 mm for both adeno-
carcinoma and squamous cell carcinoma at LRCp) 
remains the same. however, it is applied to the iGTv 
to create the internal target volume (iTv) that accounts 
for both microscopic disease and internal motion. 
Although methods currently exist to expedite the seg-
mentation of the iGTv in 4D-CT datasets [7,8,10], 
the most reliable method for 4D-CT target volume 
segmentation is still time-consuming manual segmen-
tation of the GTv for all respiratory phases and subse-
quent margin expansions for the iTv and planning 
target volume (pTv) [9]. For treatment planning pur-
poses, the pTv requires a margin expansion of 5–10 
mm upon the iTv to account for setup uncertainty.
Geometric uncertainties due to target volume seg-
mentation have recently been explored in the joint con-
text of 4D-CT imaging and lung cancer [11]. These 
studies have shown improvements over conventional 
3D-CT for mitigating uncertainty. Quantifying vari-
ability and accuracy at the treatment planning stage is 
equally important in measuring the dosimetric variabil-
ity due to segmentation-related geometric uncertainties. 
if the variability of anatomical segmentation exceeds the 
margin sizes applied to target volumes, the potential for 
geographic miss of the tumor volume and/or irradiation 
of normal tissues and organs at risk (OARs) can be 
expected to increase. Conversely, if current clinical 
margins are overly conservative in addressing geometric 
uncertainties, increased normal tissue irradiation can 
mitigate the effects of targeted radiotherapy and impact 
patient outcomes negatively due to radiation-induced 
lung injury (RiLi) and/or secondary malignancies. As 
very little literature exists on the dosimetric impact of 
target volume segmentation variability in 4D-CT-based 
NSCLC radiotherapy, this work aims to examine the 
impact of tumor volume segmentation accuracy and 
variability for iMRT treatment planning for NSCLC 
in terms of segmentation accuracy and quality when 
compared to an estimate of the ground truth.
Material and methods
Image acquisition and reconstruction
4D-CT imaging was performed on 10 patients with 
NSCLC, with patient demographics and disease infor-
mation presented in Supplementary Table i (to be 
found online at http://informahealthcare.com/doi/abs/1
0.3109/0284186x.2014.970666). Local Research Eth-
ics Board (REB) approval was obtained and all data 
was anonymized prior to segmentation. A philips 
16-slice Brilliance Big Bore CT scanner (philips Med-
ical Systems, Cleveland, Oh, uSA) was used. The 
Real-Time position Management (RpM) respiratory 
gating system (varian Medical Systems, palo Alto, CA, 
uSA) was used as a respiratory surrogate. The RpM 
system uses an infrared camera that follows reflective 
markers placed on the patient’s chest or abdomen. For 
all 10 patients, a long spiral CT scan with pitch  0.1 
was performed to cover the entire thorax. pulmonary 
signal data was collected from the RpM system simul-
taneously with CT data. CT data was then recon-
structed at 10 different respiratory phases (i). 
Respiratory phases were tagged as percentage of full 
inspiration, indicating temporal steps from one full 
inspiration phase to another (i  0, 10,..., 90%). This 
form of image reconstruction allows for visualization 
of tumor volume displacement at 10 equidistant points 
in time throughout the respiratory cycle.
Manual segmentation
The GTv was segmented on each of the 10 respira-
tory phases for 10 patients by six radiation oncologists 
at the London Regional Cancer program (LRCp) 
with clinical experience ranging from 1 to 25 years. 
Manual segmentation was performed based on radio-
logical reports and difficulty was ranked from 1 (least 
difficult) to 5 (most difficult) for each case by each 
observer (Supplementary Table i to be found online 
at http://informahealthcare.com/doi/abs/10.3109/0284
186x.2014.970666). Target volume segmentation 
was performed using default visualization parameters 
for lung tumor segmentation by all physicians in 
accordance with recommendations by Giraud et al. 
[5] (2600/1600 hu for lung window,  20/400 hu 
for the mediastinal window). GTv segmentation and 
creation of the iGTv envelope, defined as the union 
of GTv segmentation from all respiratory phases was 
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performed using MiMvista v.5.2 (MiM Software, 
Cleveland, Oh, uSA). Nodal volumes were also pres-
ent for eight out of 10 patients and were segmented 
by physicians similarly to the GTv to allow for con-
struction of a Nodal iTv, Nodal pTv and a Total pTv 
[primary  Node(s)] at the treatment planning stage. 
Experts were blinded to one another’s segmentations 
and were provided with a representative axial 2D-CT 
image indicating location of the primary GTv and 
specific node(s). Manual GTv segmentations from all 
respiratory phases were fused to create an iGTv upon 
which clinical margin expansions were applied. OARs 
were segmented by a single observer in accordance 
with the 1993 iCRu Report #62 (http://www.icru.
org/home/reports/prescribing-recording-and-report-
ing-photon-beam-therapy-report-62) to allow for a 
standardized interpretation amongst observers.
Reference segmentations
Manual segmentations of the six participating physi-
cians were incorporated into multi-expert ground 
truth estimates via the simultaneous truth and per-
formance level estimation (STApLE) algorithm to 
create reference standard segmentations in this study 
[12]. STApLE calculations were made possible with 
software provided by harvard’s Computational Radi-
ology Laboratory (CRL) and a user interface built in 
C# (Microsoft. Redmond, washington). This method 
allows for comparison of both target volume segmen-
tations and corresponding treatment plan dose dis-
tributions to a gold standard with equal bias assumed 
towards each observer. Reference target volumes 
were constructed with the same clinical margins 
applied as manual segmentations.
IMRT treatment planning
Segmentations were transferred to the pinnacleTM 
(philips Radiation Oncology Systems; Milpitas, uSA) 
treatment planning system (TpS) 9.1 Beta for iMRT 
treatment planning and dose distribution calculation. 
Treatment planning was fully automated using in-house 
scripts written in the pinnacleTM scripting language. To 
eliminate any planning bias, no plans were subject to 
any manual fine-tuning post optimization. The col-
lapsed cone convolution algorithm was selected in pin-
nacle software to compute the 3D dose matrix with 4 
mm grid spacing. Treatment planning Dvh objectives 
were chosen to comply with RTOG criteria (Trial 
0617) [13] (http://www.rtog.org/clinicaltrials/proto-
coltable/studydetails.aspx?study  0617) with a fixed 
5-beam arrangement at 6 and 10 Mv energies. Only a 
single energy was implemented in automated planning 
for individual patients across all observers and the STA-
pLE plan. Gantry angles were determined on a patient-
specific basis in efforts to achieve plans compliant with 
RTOG 0617. The target prescription dose was 60 Gy 
in 30 fractions normalized to 100% at the target’s cen-
troid. Target coverage was assessed using D95 [the dose 
to 95% of the pTv volumes (pTv-primary, pTv-
Nodes, and pTv-Total)] during treatment planning to 
ensure adequate target coverage. while RTOG 0617 
calls for assessment of target volume coverage in terms 
of the pTv-Total, this constraint was applied individu-
ally to both pTv-primary and pTv-Nodes as well to 
ensure all targets were sufficiently covered during 
dose calculation and optimization.
Segmentation comparison
Manually derived, physician segmentations were com-
pared to the STApLE segmentations for primary and 
Nodal pTvs for all 10 patients. All segmentations were 
reconstructed using a novel global optimization frame-
work in C for 3D shape reconstruction proposed 
by Lempitsky and Boykov which ensured sets of closed, 
minimal surfaces were generated for comparison [14]. 
This software also allowed for volume-based segmen-
tation comparisons, given by volume overlap error 
(vOE). Distance-based measurements, given by the 
root mean square (RMS) symmetric surface distance, 
were calculated using in-house software built in MAT-
LAB (Mathworks, Natick, MA, uSA). The vOE was 
chosen in accordance with studies performed by hei-
mann et al. [15] and Fotina et al. [16] who observed 
both the popularity of the metrics and its superiority 
compared to other volume-based metrics in the con-
text of segmentation analysis, respectively. As stated by 
heimann et al., the RMS symmetric surface distance 
metric is one of the most important in evaluating seg-
mentation accuracy [15]. The extent of variability for 
segmentation comparison is demonstrated by standard 
deviations (SD) and the coefficients of variance (COv) 
for each metric across the observer group, where the 
COv is given in percent and defined as the SD divided 
by the mean, multiplied by one hundred.
Treatment plan comparison
Treatment plans were optimized for all observer-
based target volume segmentations and STApLE 
segmentations for primary and nodal (if present) 
targets. Observer-based treatment plan dose distri-
butions were then analyzed in the context of the 
STApLE segmentation, i.e. observer-based dose 
distributions overlaid on STApLE segmentations. 
This was done to assess variable dosimetry inherent 
to each physician’s target volume segmentation 
against optimal dosimetry calculations based on 
those of the GT estimate. Several measures were 
used to assess the quality of treatment plan dose dis-
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tributions. Metrics representative of both physical 
and radiobiological dosimetric characteristics were 
used to quantitatively evaluate the variability of tar-
get volume segmentation for NSCLC radiotherapy.
in assessing the physical characteristics of 
optimized dose distributions, dose homogeneity/ 
heterogeneity calculations throughout the target 
volume were performed. homogeneity index (hi) was 
evaluated as the difference between the maximum and 
minimum dose to the target volume (D2% and D98%, 
respectively) divided by the prescription dose [17]. 
uniformity index (ui) was also used and defined as 
the ratio of D5% to D95% [18]. A value of zero for hi 
and unity for ui indicates optimal dose homogeneity.
Radiobiological parameters for assessment in this 
study included the primary tumor control probability 
(TCp) and the normal tissue complication probability 
(NTCp) for the healthy lung (defined as lung minus 
CTv-primary per RTOG 0617). For TCp calcula-
tions, a D50 of 70 Gy, a g of 2.0 were assumed and an 
(a/b) of 10. TCp calculation for this study did not take 
into account dose inhomogeneties within the target 
sub-volume. parameters for TCp calculations were 
chosen in accordance with the study performed by van 
Baardwijk et al. [19]. For NTCp calculations, the 
Lyman-kutcher-Burman (LkB) model was used 
where the estimated volume parameter was n  0.41 
as per the study by Tucker et al. who showed it better 
predicted RiLi risk compared to the MLD (n  1) 
[20]. if the Deff [or equivalent uniform dose (EuD)] 
is distributed uniformly throughout the entire volume, 
it will yield an equivalent NTCp as the actual non-
uniform dose distribution. For NTCp calculations, 
additional parameters of m  0.31, and a threshold 
dose of 43.20 Gy (TD50  43.20 Gy) were used, again 
in accordance with the study by Tucker et al. [20]. 
Radiobiology calculations were performed using in-
house software built in C (Microsoft, Redmond, 
wA, uSA) with a wrapper built in C# (Microsoft).
As previously stated, GTvs were manually 
segmented on 4D-CT data sets by six different 
radiation oncologists. however, pTv segmentations 
(iGTv  1.5cm) were compared and planned upon to 
provide insights into accuracy of treatment planning 
target volumes and subsequent dosimetric variability. 
Appropriate margin expansions were applied to iGTvs 
to construct pTvs as treatment planning in the clinical 
setting routinely assigns 95% of prescription does to 
the pTv during treatment plan optimization. in doing 
this, dosimetric characteristics based on multiple target 
volume segmentations are more appropriately analyzed 
in the context of the dose to the pTv. As such, differ-
ent segmentations and were compared to STApLE-
derived segmentations with the precisely the same 
margins to avoid any systematic errors in segmentation 
analysis and treatment plan comparison.
Results
Segmentation variability
All manual segmentation results were compared to 
their respective STApLE GT estimate segmentations 
in evaluating segmentation accuracy and quality. 
Figure 1(a) shows mean observer vOE for primary 
and nodal iGTv volumes and their respective SDs. 
For primary iGTvs, mean observer vOE ranged 
from (9.0  0.6)% to (35.6  7.5)%, with SD rang-
ing from 0.6% to 13.2%. Nodal iGTv demonstrated 
mean observer vOE ranging from (16.4  1.5)% to 
(29.1  4.1)% with SD ranging from 1.5% to 13.1%. 
Figure 1(b) shows mean observer symmetric RMS 
distances for primary and nodal iGTv segmenta-
tions compared to STApLE segmentations with 
respective SD for all patients. For primary iGTvs, 
mean observer RMS symmetric distances ranged 
from (3.4  0.4)mm to (7.8  1.8)mm, with SD 
ranging from 0.2 mm to 1.2 mm. Nodal iGTvs 
demonstrated mean observer RMS symmetric dis-
tances ranging from (4.1  0.8)mm to (6.5  0.7)
mm with SD ranging from 0.2 mm to 3.2mm.
Tables i and ii show maximum and minimum 
measures as well as coefficients of variation for both 
vOE and RMS symmetric distances, respectively. 
Looking at the COv across both vOE and RMS sym-
metric distances, nodal iGTv segmentation was 
typically subject to larger errors and variance, how-
ever, the variability was still quite high for both target 
volumes across the observer group and fluctuating 
COvs indicates the presence of outlier segmenta-
tions for each patient.
Dosimetric variability
Figure 2 demonstrates the subsequent effect of vari-
able target volume segmentation on treatment plan-
ning for a moderately variable case (patient F).
The D95 for primary and nodal pTvs is shown 
in Figure 3. primary iGTv segmentations across the 
observer segmentation groups yielded only four cases 
in which clinically acceptable target volume coverage 
of the pTv was achieved (D95  60 Gy) (patients A, 
E, G, J) (Figure 3). Nodal iGTv segmentations 
across this group yielded only one case in which 
mean observer segmentations provided for clinically 
acceptable target coverage (patient J). 
Supplementary Figure 1(a) (to be found online at 
http://informahealthcare.com/doi/abs/10.3109/ 
0284186x.2014.970666) shows mean uniformity 
indices (ui) for primary and nodal iGTvs compared 
to STApLE segmentation-based ui. For primary 
iGTvs, mean observer ui ranged from 1.1  0.10 to 
1.9  0.9, with SD ranging from 0.01 to 0.9. Nodal 
iGTv demonstrated mean observer ui ranging from 
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Figure 1. Mean observer vOE for primary and nodal iGTv volumes and their respective standard deviations (SD) for all 10 patients (a). 
Mean observer symmetric RMS distances for primary and nodal iGTv segmentations compared to STApLE segmentations with respective 
standard deviations (SD) for all patients (b).
1.1  0.1 to 1.9  0.8 with SD ranging from 0.1 to 0.8. 
Dose uniformity was consistently worse amongst 
observers compared to the STApLE-derived target 
volume dose distributions. Nodal iGTv segmentation 
typically provided for slightly increased ui and associ-
ated variance, indicative of higher segmentation uncer-
tainty being propagated into the treatment planning 
stage. Supplementary Figure 1(b) to be found online 
at http://informahealthcare.com/doi/abs/10.3109/0284
186x.2014.970666 shows mean homogeneity indices 
(hi) for primary and nodal iGTvs compared to STA-
pLE segmentation-based hi. For primary iGTvs, 
mean observer hi was routinely higher than it was for 
the STApLE-based target, ranging from (11.4  2.4)% 
to (61.1  26.5)%, with SD ranging from 2.1% to 
26.5%. Nodal iGTv demonstrated similarly higher 
A
ct
a 
O
nc
ol
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f W
es
te
rn
 O
nt
ar
io
 o
n 
04
/0
7/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
 Dosimetric impact of target volume segmentation variability  327
derived target volume. For these cases, this effect was 
due to the fact that the observer segmentation was 
smaller in volume than the STApLE volume and was 
largely contained within it. however, the mean TCp 
derived from the observer group never exceeded that 
of the STApLE target segmentation itself.
All treatment plans were able to meet RTOG 
0617 standards for all critical structures (spinal 
cord, esophagus, heart, healthy lung). OAR anal-
ysis focused on the total lung volume as it is 
directly related to target volume segmentation 
variability unlike the other critical structures 
present during treatment planning. Total lung was 
assessed based on the dose to the total lung minus 
CTvSTApLE with the total lung minus CTvObserver 
overlaid for each physician’s respective treatment 
plan dose distributions per RTOG 0617 lung-eval 
criteria. Supplementary Table ii (to be found 
online at http://informahealthcare.com/doi/abs/1
0.3109/0284186x.2014.970666) shows mean 
total lung dosimetric measures across the physi-
cian group ( SD)compared to those derived 
from the STApLE-based dose distribution. very 
little variation is present on an intra-patient basis, 
with inter-patient fluctuation occurring most 
likely as a result of varying iGTv size. Figure 5 
shows mean NTCp based on treatment plans for 
each physician-derived target volume well as the 
mean observer hi ranging from (13.4  9.2)% to 
(75.2  4.7)% with SD ranging from 2.0% to 27.6%. 
Dose homogeneity reflects a similar trend demon-
strated in ui measurements with greater sensitivity 
and magnitude of deviation. Nodal iGTv segmenta-
tions provided for increased variability and uncertainty 
in optimized dose distributions compared to primary 
iGTvs. however, the magnitude of variation varied 
between physicians on an inter-patient basis, most 
noticeably for patients B (extreme variance) and E 
(minimal variance). variability was largely inconsistent 
for both metrics. however, trends demonstrated for 
segmentation-based analysis were reflected in subse-
quent dosimetric analysis for corresponding patients 
indicating that target volume segmentation variability 
influences dosimetric uncertainty and fluctuates on 
both an inter-physician and an inter-patient basis.
Figure 4 shows mean TCp based on treatment 
plans for each physician’s primary iGTv segmenta-
tion as well as the TCp derived from STApLE-based 
treatment plans. Mean observer-based TCps were 
again subject to a wide range of variability and were 
typically lower than that of the STApLE-based TCp 
for both scenarios. For primary iGTvs, mean 
observer TCps ranged from (22.6  11.9)% to 
(33.7  0.6)%, with SD ranging from 0.5% to 11.9%. 
in certain cases, single observer segmentation was 
close to or exceeded the TCp of the STApLE- 
Table i. Maximum, minimum and COv measures for vOE.
pTv primary pTv Nodes
patient Max vOE (%) Min vOE (%) COv (%) Max vOE (%) Min vOE (%) COv (%)
A 9.85 8.36 6.30 33.18 22.83 14.20
B 40.89 10.54 41.07 37.51 21.07 26.87
C 41.71 20.99 21.93 84.10 12.82 105.75
D 40.31 5.96 93.25 18.24 14.21 9.10
E 17.66 7.14 29.28 29.67 12.48 37.59
F 34.02 15.97 25.22 --- --- ---
G 15.69 8.27 22.93 34.53 11.16 36.40
h 24.35 10.36 29.98 31.22 13.60 28.22
i 18.59 8.76 30.49 --- --- ---
J 13.56 6.14 27.57 38.50 8.41 70.29
Table ii. Maximum, minimum and COv measures for symmetric RMS distances.
pTv primary pTv Nodes
patient Max RMSD (mm) Min RMSD (mm) COv (%) Max RMSD (mm) Min RMSD (mm) COv (%)
A 4.69 4.21 4.02 7.12 5.55 10.12
B 9.61 4.05 28.56 6.95 4.88 16.44
C 9.46 5.09 23.77 11.54 3.41 63.51
D 5.17 3.59 16.06 4.71 4.34 3.47
E 4.98 3.20 14.88 5.49 3.51 18.24
F 7.53 4.92 15.30 --- --- ---
G 4.11 3.15 10.46 5.61 3.42 16.26
h 6.13 3.94 15.51 6.60 4.30 16.60
i 5.53 3.64 19.04 --- --- ---
J 4.30 3.36 9.30 7.61 3.14 37.30
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Figure 2. pTv definition for multiple physicians as well as the STApLE-based pTv estimate. The subsequent dose distributions from 
each target overlaid on the GT estimate segmentation are shown in Figure 3(b) Figure 3(b)(i)–(vi) correspond to physicians 1–6, respectively. 
The Dvh curves of healthy lung and primary pTv for each physician are subsequently shown in Figure 3(c).
NTCp derived from STApLE-based treatment 
plans. No discernible trends are present and vari-
ability appears to be patient specific.
Discussion
Multiple studies on tumor volume segmentation uncer-
tainty and variability have been performed previously. 
Studies performed in the context of both 3D- and 
4D-CT reported the effects of target volume segmenta-
tion for lung tumors with results demonstrating differ-
ent ranges of uncertainty and/or variability. The most 
commonly studied influences on segmentation-related 
geometric uncertainties are the effects of inter-/intra-
observer variability [21], the relationship between 
patients breathing patterns and image artifact presence 
[22], and tumor artifacts inherent to the 4D-CT acqui-
sition modality and/or reconstruction technique [23]. 
while numerous suggestions have been made in efforts 
to identify, mitigate and/or rectify uncertainty in the 
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presence of these sources of error, very little informa-
tion exists regarding the dosimetric and/or radiobio-
logical impact of tumor volume segmentation-related 
geometric uncertainty. Studies by Spoelstra et al. [24] 
and Le Maitre et al. [25] analyzed the effects of tumor 
volume delineation on subsequent radiotherapy plan-
ning for lung cancer. Spoelstra et al. demonstrated sig-
nificant inter-clinician variability in lung tumor 
delineation leading to confounding variability in clinical 
outcomes and emphasized a need for standardization 
of target volume segmentation. They concluded that 
uncertainty in anatomical delineation was the largest 
source of systematic error in image-guided lung cancer 
radiotherapy. This idea was extrapolated upon and rein-
forced by Jameson et al. who made similar conclusions 
in their review of segmentation analysis strategies in 
radiation oncology [26]. Le Maitre et al. examined the 
dosimetric effect of pET-based functional volume auto-
segmentation variability and demonstrated a reduction 
in dosimetric errors using more advanced segmentation 
strategies [25]. however, this study focused on func-
tional volume derived from static pET-CT images and 
lacked the influence of respiratory motion on target 
volume segmentation, which does not reflect current 
clinical practice. More recently, Jameson et al. con-
ducted a study in which they showed a strong correla-
tion between geometric uncertainties and TCp in the 
context of lung tumor segmentation [27]. Our study 
attempts to build on these works in reporting on the 
effects of GTv/iGTv segmentation accuracy and vari-
ability on iMRT treatment planning for lung tumors in 
the context of 4D-CT imaging and respiratory motion. 
The results of this study suggest that a wide range of 
variability within 4D-CT-derived tumor volume seg-
mentations extends into the treatment planning stages 
of iMRT and affects both physical and radiobiological 
characteristics of the calculated dose distributions. The 
largest variability resulted from comparison of primary 
and nodal target volume dose distributions as well as 
inter-patient comparison. The dosimetric uncertainty 
that arises due to variable primary and nodal iGTv 
segmentations is most likely attributed the vastly differ-
ent geometry between these structures. Nodal targets 
were routinely smaller than primary target volumes and 
accordingly, geometric differences of the same magni-
tude have different relative effects on both segmenta-
tion accuracy and dosimetric variability. Nodal volumes 
can be quite difficult to identify within 3D image vol-
umes without contrast enhancement as they typically 
reside in areas of low contrast and defining normal ver-
sus abnormal lymph nodes can be a challenge without 
functional and/or metabolic imaging, such as positron 
emission tomography (pET)-CT [28] and dynamic 
contrast-enhanced (DCE) magnetic resonance imag-
ing (MRi) [29]. This issue is challenging to address in 
the context of segmentation variability, as it is subject 
to increased inter-/intra-observer variance as well. pre-
vious studies indicated that pET-CT could be valuable 
in helping to more accurately identify abnormal nodes 
in lung cancer patients [6,28]. Subsequently, advanced 
imaging strategies incorporating functional information 
and/or metabolic information could possibly incur 
advantages in reducing dosimetric variability at the 
treatment planning stage for nodal target volumes. 
inter-patient dosimetric uncertainty is considerably 
more difficult to mitigate.
Lung tumor geometry is inherently patient specific 
and highly variable factors contribute to varying levels 
Figure 3. Mean D95 for primary and nodal pTvs based on observer segmentations as well as D95 from STApLE-based iGTv.
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of segmentation difficulty for each incoming case 
viewed by physicians in clinic. For this study, a wide 
range of patients were selected to quantify the dosim-
etric impact of target volume segmentation accuracy 
and variability on treatment planning for lung cancer 
patients. however, this presents as a limitation in this 
study. Analysis showed a correlation between dosimet-
ric variability and patient-specific characteristics such 
as tumor volume, location, and segmentation difficulty 
as scored by observers. Therefore, further sub-classifi-
cation based on patient-specific characteristics prior to 
analysis would be beneficial for future studies focused 
on quantifying segmentation-related variability in the 
treatment planning context. Another limitation in this 
study is the small number of patients and observers. 
while only 10 patients and six observers were utilized, 
this provided for approximately 600 manually defined 
primary and nodal iGTv segmentations, yielding a 
considerable amount of data for this and future studies. 
it is important to note that considerably more informa-
tion can be acquired and studied in the context of 
4D-CT compared to other conventional image acqui-
sition techniques with a relatively low number of 
patients and observers when needed. Such observa-
tions may prove valuable in future work with sub- 
classified groups where limited patient data is available. 
Additionally, the inclusion of surgical specimens and/
or tumor pathology would help to verify the accuracy 
of the STApLE algorithm. Currently, STApLE only 
gives us a ground truth estimate based solely on image 
information. Further verification of the algorithm in 
the context of lung tumors analogous to the work of 
Gordon et al. [30] would validate studies such as ours 
working towards the reduction of segmentation-related 
geometric uncertainties.
One of the most common solutions presented for 
mitigating geometric uncertainties in target volume 
segmentation is automatic and/or semi-automatic seg-
mentation. These strategies rely on the notion that by 
reducing the amount of manual target volume segmen-
tation, inter- and intra-observer variance can be greatly 
reduced and the consistency and integrity of segmen-
tation is increased without sacrificing accuracy. how-
ever, auto-segmentation strategies pose considerable 
difficulty in both development and implementation. 
Segmentation must be at least as accurate as manual 
strategies while also being computationally efficient. in 
cases where auto-segmentation is used for iGRT, auto-
matic techniques must be validated and incorporated 
into the routine clinical framework. Automated seg-
mentation techniques have been proposed to utilize 
different approaches [8,31]. These techniques gener-
ally provide a starting point for target delineation in 
the clinical setting, subject to review and edit by physi-
cians. The possibility of amalgamating ground truth 
estimation techniques, such as STApLE [14], that are 
based on multiple manual observer segmentations with 
auto-segmentation techniques utilizing a priori infor-
Figure 4. Mean TCp for primary iGTvs based on observer segmentations as well as TCp from STApLE-based treatment plan.
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mation could complement existing strategies in reduc-
ing inter- and intra-observer variability. This type of 
strategy could be augmented by some form of col-
league peer-review [32] but would entail an exception-
ally complex clinical segmentation framework for 
efficient utilization. Another possible solution to 
address this problem could be the initiation of multi-
institution, multi-observer studies focused on deter-
mining clinical margins to compensate for uncertainties 
based on target volume definition. These margins 
could be determined for a variety of treatment tech-
niques with varying degrees of conformity and differ-
ent dose prescriptions, i.e. stereotactic body radiation 
therapy/stereotactic ablative radiation therapy (SBRT/
SABR) and 3D-conformal radiation therapy (3D-CRT). 
Much like the margins that exist to account for micro-
scopic disease, inter-fraction motion and/or setup 
error, clinical margins could be developed to account 
for geometric uncertainties arising in the process of 
target volume segmentation for all available treatment 
techniques. however, this would also necessitate large-
scale segmentation studies consisting of multiple 
observers across multiple institutions as well as exten-
sive validation to be fully accepted at the clinical level. 
Additionally, the inclusion of supplementary informa-
tion such as that provided by hybrid and/or functional/
metabolic imaging would require different sets of 
guidelines depending on the diagnostic information 
that is available and the disease pathology. while there 
is no immediate solution to this problem, there are a 
number of different tools and research possibilities to 
address it as diagnostic imaging and radiotherapy tech-
niques evolve.
in conclusion, a considerable amount of variabil-
ity currently exists in target volume segmentation for 
lung tumors in the context of 4D-CT imaging. Based 
on primary and nodal lung tumor target segmenta-
tions amongst multiple experts in the presence of a 
reference standard, this variability extends into the 
treatment planning stages for iMRT. Although the 
use of 4D-CT allows for more accurate target volume 
segmentation by accounting for respiratory motion, 
further improvements need to be made to provide for 
more consistent target volume segmentation. 
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